Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7051 to 7065 of 7707 results

  1. Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events (TA90)

    This guideline has been updated and replaced by NICE technology appraisal 210.

    Technology appraisal guidance
    Published
    25 May 2005

  2. Immunosuppressive therapy for renal transplantation in children and adolescents (TA99)

    This guidance has been updated and replaced by NICE technology appraisal guidance 482.

    Technology appraisal guidance
    Published
    26 April 2006

  3. Statins for the prevention of cardiovascular events (TA94)

    This guidance has been updated and replaced by NICE guideline CG181.

    Technology appraisal guidance
    Published
    25 January 2006

  4. Dementia: support in health and social care (QS1)

    This quality standard has been updated and replaced by NICE quality standard 184. 

    Quality standard
    Published
    29 June 2010

  5. Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies (TA669)

    This guidance has been updated and replaced by NICE technology appraisal guidance 852.

    Technology appraisal guidance
    Published
    27 January 2021

  6. The clinical effectiveness and cost effectiveness of amantadine and oseltamivir for the prophylaxis of influenza (TA67)

    This guidance has been updated and replaced NICE technology appraisal guidance 158.

    Technology appraisal guidance
    Published
    24 September 2003

  7. The clinical and cost effectiveness of proton pump inhibitors for the treatment of dyspepsia (TA7)

    This guidance has been replaced by NICE guideline CG17. [Replaced by NICE guideline CG184]

    Technology appraisal guidance
    Published
    23 July 2000

  8. Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal) (TA652)

    This guidance has been updated and replaced by NICE technology appraisal guidance 816.

    Technology appraisal guidance
    Published
    7 October 2020

  9. Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA711)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA815.

    Technology appraisal guidance
    Published
    30 June 2021

  10. Teduglutide for treating short bowel syndrome (terminated appraisal) (TA690)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA804.

    Technology appraisal guidance
    Published
    21 April 2021

  11. Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer (TA693)

    This guidance has been updated and replaced by NICE technology appraisal guidance 946.

    Technology appraisal guidance
    Published
    28 April 2021

  12. Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA619)

    This guidance has been updated and replaced by NICE technology appraisal guidance 836.

    Technology appraisal guidance
    Published
    15 January 2020

  13. Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA620)

    This guidance has been updated and replaced by NICE technology appraisal guidance 908.

    Technology appraisal guidance
    Published
    15 January 2020

  14. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA621)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 654 

    Technology appraisal guidance
    Published
    22 January 2020

  15. Newer drugs for epilepsy in children (TA79)

    This guideline has been updated and replaced by NICE guideline CG137.

    Technology appraisal guidance
    Published
    28 April 2004